SEC Form 4 · accession 0001104659-18-019018
Voyager Therapeutics, Inc. · VYGR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jane Henderson
Officer — CFO & SVP, Corp. Dev.
Period of report
Mar 16, 2018
Accepted (ET)
Mar 20, 2018 · 5:43 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001640266
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 16, 2018 | M | 15,416 | $11.97 | A | 15,416 | D | |
| Common StockF1 | Mar 16, 2018 | S | 15,416 | $22.15 | D | 0 | D | |
| Common Stock | Mar 19, 2018 | M | 1,900 | $11.97 | A | 1,900 | D | |
| Common StockF2 | Mar 19, 2018 | S | 1,900 | $21.76 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $11.97 | Mar 16, 2018 | M | 15,416 | D | — | Jan 3, 2027 | Common Stock | 15,416 | 198,584 | D |
| Stock Option (Right to Buy)F3 | $11.97 | Mar 19, 2018 | M | 1,900 | D | — | Jan 3, 2027 | Common Stock | 1,900 | 196,684 | D |
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.00 to $22.42, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., any security holder of Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.75 to $21.80, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., any security holder of Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
- F3This stock option was issued pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan. The option vests over four years, with 53,500 of the shares of common stock underlying the option vesting on 1/1/2018 and the remainder vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service.